Nordicus Partners Corporation, a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces it has applied to uplist its common stock (the “Common Stock”) to the Nasdaq Capital Market (“Nasdaq”). The Common Stock will continue to trade on the OTCQB Market until the uplisting is approved.
“We are pleased to announce our application to uplist our shares on Nasdaq,” said Henrik Rouf, Nordicus’ Chief Executive Officer. “Following the completion of two acquisitions last year, and with the advancement of our proprietary drug development pipeline in periodontitis and oral leukoplakia, we believe the time is right to move to a globally recognized exchange. A Nasdaq listing will not only provide greater visibility and liquidity for our shareholders, but also strengthen our ability to attract institutional investors and access capital on more favorable terms to accelerate the growth of our business.”
The listing of Nordicus’ Common Stock on Nasdaq is subject to the approval of Nasdaq and the satisfaction of all applicable listing criteria and requirements. We are confident that Nordicus will meet all applicable listing criteria and requirements, but no assurance can be given that such application will be approved or that such listing will be completed. The Common Stock will continue to trade on the OTCQB under its current symbol NORD pending approval of a Nasdaq listing.
Read More on Fintech : Reinventing Identity Security in the Age of AI
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert A/S, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia
Catch more Fintech Insights : The Future of Banking Starts with Customers
[To share your insights with us, please write to psen@itechseries.com ]
